Last reviewed · How we verify

Rajaie Cardiovascular Medical and Research Center — Portfolio Competitive Intelligence Brief

Rajaie Cardiovascular Medical and Research Center pipeline: 0 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
intermediate dose Enoxaparin/ unfractionated heparin intermediate dose Enoxaparin/ unfractionated heparin phase 3 Low molecular weight heparin Antithrombin Cardiovascular
Six percent hydroxy ethyl starch 130/0.4 Six percent hydroxy ethyl starch 130/0.4 phase 3 Synthetic colloid / Volume expander Cardiovascular / Critical Care

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Aalborg University Hospital · 1 shared drug class
  2. China International Neuroscience Institution · 1 shared drug class
  3. Queen Mary University of London · 1 shared drug class
  4. VarmX B.V. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Rajaie Cardiovascular Medical and Research Center:

Cite this brief

Drug Landscape (2026). Rajaie Cardiovascular Medical and Research Center — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/rajaie-cardiovascular-medical-and-research-center. Accessed 2026-05-17.

Related